{"denoms":[{"counts":[{"groupId":"BG000","value":"6"}],"units":"Participants"}],"groups":[{"description":"Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.\n\nCyclophosphamide: Given intravenously (IV)\n\nFludarabine: Given IV\n\nG-CSF: Given IV or subcutaneously (SQ)\n\nInterleukin-2: Given SQ\n\nMelphalan: Given IV\n\nThiotepa: Given IV\n\nRituximab: Given IV\n\nNatural killer cell therapy: Given IV\n\nT-cell depleted HPC transplant: T-cell depleted hematopoietic stem cells will be infused on day 0.\n\nCD45RA-depleted HPC transplant: CD45RA depleted stem cells will be infused on day 1.","id":"BG000","title":"Participants"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"5.5","value":"12.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6.7","upperLimit":"19.5","value":"12.2"}]}],"title":"Age, Median"}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Not otherwise specified Spanish, Hispanic, Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Non Spanish speaking, Non Hispanic"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"AML with 11q23/MLL abnormalities"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"AML, multilineage dysplasia with prior MDS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"AML, not otherwise specified"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"AML, without maturation"}],"description":"AML = acute myeloid leukemia; MLL = myeloid-lymphoid leukemia; MDS = myelodysplastic syndrome","paramType":"NUMBER","title":"Primary Diagnosis","unitOfMeasure":"participants"}]}